{"entity":{"type":"insider","cik":"0001385625","url":"/insider/0001385625","json_url":"/insider/0001385625.json","name":"Leadiant Biosciences, Inc.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":9,"n_filings":4,"first":"2009-02-13","last":"2017-12-01","span_basis":"filed_date"},"name_variants":[{"name":"Leadiant Biosciences, Inc.","source":"filing","n_filings":1,"first_seen":"2017-12-01","last_seen":"2017-12-01"},{"name":"Sigma-Tau Pharmaceuticals, Inc.","source":"filing","n_filings":3,"first_seen":"2009-02-13","last_seen":"2010-06-21"}],"transactions":[{"id":4232005,"accession":"0001213900-17-012851","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001213900-17-012851","line_url":"/filing/0001213900-17-012851","is_derivative":false,"issuer_cik":"0000812796","issuer_name":"SOLIGENIX, INC.","issuer_ticker":"SNGX","issuer_name_source":null,"issuer_url":"/issuer/0000812796","owner_cik":null,"owner_name":"Cavazza Silvia; Cavazza Enrico; Cavazza Preta Martina; Cavazza Francesca; Essetifin SPA; Leadiant Biosciences, Inc.; CAVAZZA PAOLO","owner_display_name":"Cavazza Silvia","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":293510.0,"shares_display":"293,510","price_per_share":2.12,"price_display":"2.12","price_state":"stated","total_value":622241.2,"total_display":"622,241.20","total_whole":"622,241","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-11-29","filed_date":"2017-12-01","scope":"insider","n_lines":3},{"id":4231990,"accession":"0001213900-17-012851","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-17-012851","line_url":"/filing/0001213900-17-012851","is_derivative":false,"issuer_cik":"0000812796","issuer_name":"SOLIGENIX, INC.","issuer_ticker":"SNGX","issuer_name_source":null,"issuer_url":"/issuer/0000812796","owner_cik":null,"owner_name":"Cavazza Silvia; Cavazza Enrico; Cavazza Preta Martina; Cavazza Francesca; Essetifin SPA; Leadiant Biosciences, Inc.; CAVAZZA PAOLO","owner_display_name":"Cavazza Silvia","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":293510.0,"shares_display":"293,510","price_per_share":2.12,"price_display":"2.12","price_state":"stated","total_value":622241.2,"total_display":"622,241.20","total_whole":"622,241","shares_owned_after":271140.0,"shares_owned_after_display":"271,140","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-11-29","filed_date":"2017-12-01","scope":"insider","n_lines":3},{"id":7403517,"accession":"0001140361-10-026302","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-10-026302","line_url":"/filing/0001140361-10-026302#line-1","is_derivative":false,"issuer_cik":"0000812796","issuer_name":"SOLIGENIX, INC.","issuer_ticker":"SNGX","issuer_name_source":null,"issuer_url":"/issuer/0000812796","owner_cik":null,"owner_name":"SIGMA TAU INTERNATIONAL SA; Sigma-Tau America S.A.; SIGMA TAU FINANZIARIA SPA; Sigma-Tau Pharmaceuticals, Inc.","owner_display_name":"SIGMA TAU INTERNATIONAL SA","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8608580.0,"shares_display":"8,608,580","price_per_share":0.205,"price_display":"0.20","price_state":"stated","total_value":1764758.9,"total_display":"1,764,758.90","total_whole":"1,764,759","shares_owned_after":54227816.0,"shares_owned_after_display":"54,227,816","ownership_form":"I","is_10b5_1":null,"transaction_date":"2010-06-18","filed_date":"2010-06-21","scope":"insider"},{"id":5709272,"accession":"0001140361-09-021821","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-09-021821","line_url":"/filing/0001140361-09-021821#line-1","is_derivative":false,"issuer_cik":"0000812796","issuer_name":"DOR BIOPHARMA INC","issuer_ticker":"DORB","issuer_name_source":null,"issuer_url":"/issuer/0000812796","owner_cik":null,"owner_name":"SIGMA TAU INTERNATIONAL SA; Sigma-Tau Pharmaceuticals, Inc.; SIGMA TAU FINANZIARIA SPA; Sigma-Tau America S.A.","owner_display_name":"SIGMA TAU INTERNATIONAL SA","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3952569.0,"shares_display":"3,952,569","price_per_share":0.253,"price_display":"0.25","price_state":"stated","total_value":999999.957,"total_display":"999,999.96","total_whole":"1,000,000","shares_owned_after":45619236.0,"shares_owned_after_display":"45,619,236","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-09-24","filed_date":"2009-09-28","scope":"insider"},{"id":5858244,"accession":"0001140361-09-003871","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-09-003871","line_url":"/filing/0001140361-09-003871#line-1","is_derivative":false,"issuer_cik":"0000812796","issuer_name":"DOR BIOPHARMA INC","issuer_ticker":"DORB","issuer_name_source":null,"issuer_url":"/issuer/0000812796","owner_cik":null,"owner_name":"SIGMA TAU FINANZIARIA SPA; Sigma-Tau Pharmaceuticals, Inc.; Sigma-Tau America S.A.; SIGMA TAU INTERNATIONAL SA","owner_display_name":"SIGMA TAU FINANZIARIA SPA","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":25000000.0,"shares_display":"25,000,000","price_per_share":0.18,"price_display":"0.18","price_state":"stated","total_value":4500000.0,"total_display":"4,500,000.00","total_whole":"4,500,000","shares_owned_after":41666667.0,"shares_owned_after_display":"41,666,667","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-02-11","filed_date":"2009-02-13","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000812796","name":"SOLIGENIX, INC.","url":"/issuer/0000812796","role":"Ten percent owner, Other","n_filings":4,"first_seen":"2009-02-13","last_seen":"2017-12-01"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001385625","retrieved_at":"2026-08-25T00:22:43+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}